A name and a question
Why Sermorelin Doctor exists
The original diagnostic use supplies the question: what has actually been established by the response?
About the Sermorelin Doctor name
Sermorelin Doctor contains my examination of published research; nothing here is medical advice. I’m no doctor; ‘Doctor’ is the site’s name. The site offers no prescriptions, sales, shipments or bookings.
An unresolved examination is harder for me to dismiss than a tidy promise. A drug that once helped test a gland now appears in much broader claims about aging. The diagnostic history gives those claims an unusually concrete starting point. A hormone response can be useful information without answering every question asked of it.
My sympathy is with the awkward results: the small infusion study whose early response faded, for example. It makes the tidy version harder to tell and the biology more interesting.
The history has been flattened in both directions
The shorthand ‘never approved’ loses a real clinical history. Treating that history as approval of today’s adult wellness claims loses the limits of the old indication. Neither account satisfies me.
Approval, withdrawal and compounding
Sermorelin acetate had an FDA-approved role in diagnosis and in treating children with growth hormone deficiency and short stature. The pediatric review records those uses. US sales ended in 2008 for commercial reasons, not safety or efficacy problems; a subsequent clinical review examined the loss of a commercially available GHRH diagnostic agent.
Sermorelin is now prepared by compounding pharmacies for individual patients under prescription. It is treated as a Category 1 bulk drug substance under FDA’s interim Section 503A policy, with final guidance issued in January 2025. The agency’s interim enforcement approach is not approval of a compounded medicine. Each compounded preparation has no FDA approval of its own.
That distinction is worth the extra sentence. An old indication, a commercial withdrawal and a present compounding policy answer different regulatory questions.
A result that would change the argument
I’d welcome a convincing adult outcome trial that measures the things usually promised and follows safety long enough to make the result useful. The anti-aging caution is persuasive because those questions remain open, not because hormone changes are imaginary. A correction to a claim here belongs on the contact page, ideally with the paper and the exact passage.